-
The most common way to investigate the functions of miRNAs is to inhibit them one at a time.
-
The American Heart Association (AHA; Dallas) recently reported that U.S. deaths from heart disease and stroke dropped about 25% from 1999 to 2005, five years ahead of goals.
-
diaDexus (San Francisco) has received FDA clearance for a new automated version of its PLAC Test.
-
-
Heart drugs aren't all that controversial, but the approval of the heart failure drug BiDil raised some interesting questions. And its future is currently in doubt.
-
Cytori Therapeutics (San Diego) reported receiving its first orders from Europe and Asia for Celution 800 Systems. Eleven Celution 800 Systems and related CT-805 single-use consumables were ordered by Cytori's distributors MBA Grupo, which covers Spain, Italy, and Portugal, and Astrea International, which covers Singapore. Cytori says the first devices are to be delivered this quarter.
-
FORT LAUDERDALE, Florida The field of cardiothoracic surgery is clearly in transition not a new development but one heightened by a variety of pressures, professional, technological, political and economic. This assertion was highlighted in a variety of ways at the organizations annual meeting here in late January.
-
Ablation Frontiers (Carlsbad, California) reported receiving FDA approval to extend U.S. enrollment in its clinical trial for interventional treatment of chronic AF.
-
BOSTON How often do you hear one of the world's most renowned and veteran physicians describe the state of knowledge in his own subspecialty as "overwhelmingly ignorant" especially if that physician is the organizer of an outstanding annual conference focused on that subspecialty?
-
Tumor lysis syndrome (TLS) is a serious and life-threatening complication that is frequently seen following initiation of chemotherapy.
